The rising prevalence of allergic diseases and severe asthma is driving steady growth in the Omalizumab Injection Market. Omalizumab is a monoclonal antibody that targets immunoglobulin E (IgE) and is widely prescribed for moderate-to-severe allergic asthma, chronic spontaneous urticaria (chronic hives), and selected allergic conditions. According to WiseGuyReports, the global omalizumab...